Best Healthcare Stocks to Buy After the Market Pullback

CMS proposed Medicare Advantage rates rising just 0.09% YoY pressures CVS Health's insurance margins; CVS reported solid Q4 revenue but rising costs triggered a post-earnings sell-off and management is scaling back MA operations to focus on profitability while leveraging retail footprint and patient relationships. AbbVie expects Skyrizi and Rinvoq to combine for more than $31 billion in sales this year, offsetting Humira's post-2023 patent-exclusivity decline, and its 54-year dividend growth streak underscores income-oriented appeal.

Analysis

The market is treating one firm as a secular, idiosyncratic growth story and the other as a cyclical/commodity-like business undergoing re‑pricing. That bifurcation creates a two-way volatility opportunity: downside shocks to insurer economics transmit rapidly to the equity via enrollment and reserve re-estimates, while positive pipeline or label wins compound investor sentiment for the drugmaker because clinical readouts are high information events with asymmetric upside.

Second-order competitive effects matter more than headline fundamentals. If a large vertically-integrated retailer pares back insurance risk, national MA carriers and regional plans will selectively acquire profitable cohorts and gain margin tailwinds; meanwhile the retailer can redeploy capital into specialty pharmacy, home-delivery and in-store clinic expansions where unit economics and cross-sell are higher, concentrating retail-side earnings power even as underwriting compresses.

Key catalysts and tail-risks sit on different horizons: expect 1–6 month sensitivity to enrollment flows, guidance revisions and post-earnings sentiment; 6–24 month sensitivity to payer formulary decisions and biosimilar adoption curves; and 12–36+ month sensitivity to large molecule clinical/regulatory outcomes. The practical implication is tradeable event risk (earnings and regulatory windows) and a multi-year asymmetric upside if development programs clear regulatory gates — while downside is concentrated and can manifest quickly if payers force aggressive step-therapy or accelerate biosimilar uptake.

Key Decisions for Investors

• Long ABBV equity (2–4% NAV): 12–36 month hold. Rationale: dividend cushions drawdown while development/label catalysts deliver asymmetric upside. Risk/reward: target 30–40% total return; initial hard stop at -15% to control binary readout risk.
• ABBV long-dated call spread (buy 18–30 month LEAP call / sell higher strike): small allocation (0.5–1% NAV). Structure to cap premium and monetize time to readouts — objective 2–4x payoff on positive Phase III/approval outcomes; max loss = paid premium.
• CVS directional hedge — buy 6–12 month put spread sized to 1–2% NAV (limited-risk bearish exposure): trade the next enrollment/guidance window. Target 20–35% directional move; exit if underlying rises >10% or retailer announces a clear margin-recovery plan.
• Pair trade — equal-notional long ABBV / short CVS for 6–18 months: capitalizes on relative rerating. Positioning: size to 1–3% net exposure; expected skewed payoff if drugmaker catalysts hit while retail/insurance pressures persist. Use spread stops if divergence compresses by >50% of initial spread.